VHL expression level in the pathological tissue is significantly associated with clinical outcomes of platinum-based chemotherapy in non-small cell lung cancer patients

  1. Cao, yejun
  2. Wang, Lingwei
  3. Zhang, Qiying
  4. Han, Yang
  5. Ma, Liang
  6. Liu, Jie
  7. Wang, Jinyi
  8. Sun, Zhengliang
  9. Zhao, Tian
  10. Chen, Guohan
  11. Hong, Xuan

Download
document - 2022-04-29T150854.744.pdf 429,14KB
WeightNameValue
1000 Titel
  • VHL expression level in the pathological tissue is significantly associated with clinical outcomes of platinum-based chemotherapy in non-small cell lung cancer patients
1000 Autor/in
  1. Cao, yejun |
  2. Wang, Lingwei |
  3. Zhang, Qiying |
  4. Han, Yang |
  5. Ma, Liang |
  6. Liu, Jie |
  7. Wang, Jinyi |
  8. Sun, Zhengliang |
  9. Zhao, Tian |
  10. Chen, Guohan |
  11. Hong, Xuan |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-02-20
1000 Erschienen in
1000 Quellenangabe
  • 6(1):283
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.17629/www.diagnosticpathology.eu-2020-6:283 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • OBJECTIVE: To investigate the association between expression level of VHL in pathological tissue and outcomes of platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. METHODS: The pathological samples of NSCLC patients were obtained for immunohistochemical staining to evaluate the expression level of VHL. Furthermore, their clinical data were collected and prognosis was traced by phone. The correlation between gene expression level and the hematotoxicity was evaluated by chi-square test. The influence of VHL expression level on the risk of hematotoxicity was tested by logistic regression model. The survival curve was plotted by Kaplan-Meier method and the survival rate between the two groups was compared by log-rank test. RESULTS: A total of 110 NSCLC patients were enrolled in this study, the median follow-up time of these patients was 27.5 months. In the whole group, 31 patients had died by the last date of follow-up to get their survival information (Nov.10,2020), with a median survival time of 24.3 months. Though immunohistochemical analysis,we found that 59 patients(53.6%) had weak expression level of VHL or lack of expression in their tumor tissues,while 51 patients(46.4%) presented moderate or high expression. We found that the patients with weak expression of VHL in their carcinoma tissue or lack of expression had more opportunities to occur neutropenia after platinum-based chemotherapy(OR=0.264,95%CI=0.085-0.818,P-value=0.021).And the expression level of VHL was correlated with OS(Logrank test：P-value= 0.007，HR= 4.219,95%CI: 1.75-10.174, P-value=0.001), while not related with DFS(Logrank test：P-value=0.256，HR= 1.334,95%CI:0.642-2.769, P-value=0.440). CONCLUSION: The expression level of VHL gene in pathological tissue is related with Granulocytosis and leukocytotoxicity after platinum-based chemotherapy in NSCLC patients. It can be used as a biomarker to predict the risk of neutropenia and the prognosis of NSCLC patients.
1000 Sacherschließung
gnd 1206347392 COVID-19
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/Q2FvLCB5ZWp1bg==|https://frl.publisso.de/adhoc/uri/V2FuZywgTGluZ3dlaQ==|https://frl.publisso.de/adhoc/uri/WmhhbmcsIFFpeWluZw==|https://frl.publisso.de/adhoc/uri/SGFuLCBZYW5n|https://frl.publisso.de/adhoc/uri/TWEsIExpYW5n|https://frl.publisso.de/adhoc/uri/TGl1LCBKaWU=|https://frl.publisso.de/adhoc/uri/V2FuZywgSmlueWk=|https://frl.publisso.de/adhoc/uri/U3VuLCBaaGVuZ2xpYW5n|https://frl.publisso.de/adhoc/uri/WmhhbywgVGlhbg==|https://frl.publisso.de/adhoc/uri/Q2hlbiwgR3VvaGFu|https://frl.publisso.de/adhoc/uri/SG9uZywgWHVhbg==
1000 Hinweis
  • withdrawn / zurückgezogen 03/11/2021
1000 Label
1000 Förderer
  1. Verein für den biol. technol. Fortschritt in der Medizin, Heidelberg |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Verein für den biol. technol. Fortschritt in der Medizin, Heidelberg |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6433321.rdf
1000 Erstellt am 2022-04-29T15:08:39.486+0200
1000 Erstellt von 218
1000 beschreibt frl:6433321
1000 Bearbeitet von 25
1000 Zuletzt bearbeitet 2024-01-09T08:46:36.125+0100
1000 Objekt bearb. Tue Jan 09 08:46:35 CET 2024
1000 Vgl. frl:6433321
1000 Oai Id
  1. oai:frl.publisso.de:frl:6433321 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source